- Home
- PTGX vs AAPG Comparison
PTGX vs AAPG Comparison
Compare PTGX & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- AAPG
- Stock Information
- Founded
- PTGX 2006
- AAPG 2009
- Country
- PTGX United States
- AAPG China
- Employees
- PTGX N/A
- AAPG N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- AAPG Biotechnology: Pharmaceutical Preparations
- Sector
- PTGX Health Care
- AAPG Health Care
- Exchange
- PTGX Nasdaq
- AAPG Nasdaq
- Market Cap
- PTGX 4.0B
- AAPG 3.6B
- IPO Year
- PTGX 2016
- AAPG 2025
- Fundamental
- Price
- PTGX $67.02
- AAPG $37.05
- Analyst Decision
- PTGX Strong Buy
- AAPG Buy
- Analyst Count
- PTGX 8
- AAPG 1
- Target Price
- PTGX $71.13
- AAPG N/A
- AVG Volume (30 Days)
- PTGX 1.0M
- AAPG 8.3K
- Earning Date
- PTGX 11-06-2025
- AAPG 11-06-2025
- Dividend Yield
- PTGX N/A
- AAPG N/A
- EPS Growth
- PTGX N/A
- AAPG N/A
- EPS
- PTGX 0.80
- AAPG N/A
- Revenue
- PTGX $209,180,000.00
- AAPG $54,524,554.00
- Revenue This Year
- PTGX N/A
- AAPG N/A
- Revenue Next Year
- PTGX $243.08
- AAPG $368.64
- P/E Ratio
- PTGX $81.13
- AAPG N/A
- Revenue Growth
- PTGX N/A
- AAPG N/A
- 52 Week Low
- PTGX $33.31
- AAPG $16.50
- 52 Week High
- PTGX $68.26
- AAPG $48.45
- Technical
- Relative Strength Index (RSI)
- PTGX 64.38
- AAPG 40.73
- Support Level
- PTGX $62.24
- AAPG $39.02
- Resistance Level
- PTGX $66.87
- AAPG $40.23
- Average True Range (ATR)
- PTGX 2.42
- AAPG 0.74
- MACD
- PTGX -0.09
- AAPG 0.07
- Stochastic Oscillator
- PTGX 86.69
- AAPG 0.00
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.